(Q33851989)

29 July 2017

1 reference

title

Opportunistic infections and other clinical manifestations of HIV disease in children (English)

1 reference

29 July 2017

main subject

opportunistic infection

1 reference

Abrams EJ

1

1 reference

29 July 2017

publication date

1 February 2000

1 reference

Pediatric Clinics of North America

29 July 2017

published in

1 reference

29 July 2017

volume

47

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

79-108

1 reference

Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Invasive bacterial infections in children born to women infected with human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Antibodies to pneumococcal capsular polysaccharides in children with human immunodeficiency virus infection given polyvalent pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Antibody responses to bacterial toxoids in children infected with human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Pneumocystis carinii pneumonia in young children with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Diagnostic bronchoalveolar lavage in children with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Cytomegalovirus infection in human immunodeficiency virus type 1-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Tran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Streptococcus pneumoniae bacteremia in children infected with HIV: presentation, course, and outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Cytomegalovirus Infection in Patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Atovaquone Compared with Dapsone for the Prevention ofPneumocystis cariniiPneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Discontinuation of Primary Prophylaxis againstPneumocystis cariniiPneumonia in HIV-1–Infected Adults Treated with Combination Antiretroviral Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Streptococcus pneumoniae in human immunodeficiency virus type 1-infected children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Antibody responses to Haemophilus influenzae type b and Streptococcus pneumoniae vaccines in children with human immunodeficiency virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Cytomegalovirus and Pneumocystis carinii pneumonia in children with acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Simultaneous Pneumocystis carinii and pneumococcal pneumonia in human immunodeficiency virus-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Cryptococcosis in human immunodeficiency virus-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Risk factors for fungemia in children infected with human immunodeficiency virus: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Congenital infection with Toxoplasma gondii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Tuberculosis in human immunodeficiency virus-exposed or -infected United States children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Tuberculosis in patients with human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Mycobacterium avium complex infection in the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Role of tissue diagnosis in pulmonary involvement in pediatric human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Varicella-zoster virus infections in children infected with human immunodeficiency virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

CD4 T-Lymphocyte Counts and Pneumocystis carinii Pneumonia in Pediatric HIV Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Bacterial infections in human immunodeficiency virus-infected children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Abnormalities of B-Cell Activation and Immunoregulation in Patients with the Acquired Immunodeficiency Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Defining the population of human immunodeficiency virus-infected children at risk for Mycobacterium avium-intracellulare infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Pneumocystis carinii pneumonia prophylaxis and early clinical manifestations of severe perinatal human immunodeficiency virus type 1 infection. Northern California Pediatric HIV Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Invasive pneumococcal infections in human immunodeficiency virus-infected children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Etiology of acute otitis media in human immunodeficiency virus-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Effect of corticosteroids on survival of children with acquired immunodeficiency syndrome and Pneumocystis carinii-related respiratory failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Opportunistic infections occurring during highly active antiretroviral treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Prophylactic Intravenous Immunoglobulin in HIV-Infected Children With CD4+ Counts of 0.20×109/L or More

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Sinusitis in children infected with human immunodeficiency virus: clinical characteristics, risk factors, and prophylaxis. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Characteristics of acute pneumonia in human immunodeficiency virus-infected children and association with long term mortality risk. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobuli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Disease patterns and survival after acquired immunodeficiency syndrome diagnosis in human immunodeficiency virus-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Tuberculosis in children infected with human immunodeficiency virus: a report of five cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Pneumocystis carinii pneumonia despite prophylaxis in children with human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Failure of intravenous pentamidine prophylaxis for Pneumocystis carinii pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Immune deficiency syndrome in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Induced sputum to diagnose Pneumocystis carinii pneumonia in immunosuppressed pediatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Immunity to Haemophilus influenzae type b polysaccharide capsule in children with human immunodeficiency virus infection immunized with a single dose of Haemophilus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Adverse reactions to trimethoprim-sulfamethoxazole among children with human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Bacterial infections in human immunodeficiency virus type 1-infected children: the impact of central venous catheters and antiretroviral agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Helper T-cell responses in children infected with human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Responses to measles immunization in children infected with human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Mycobacterium avium intracellulare complex infection in HIV-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Protease inhibitor therapy in children with perinatally acquired HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Acquired immunodeficiency syndrome in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Survival in children with perinatally acquired human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Effect of prophylaxis on the clinical manifestations of AIDS-related opportunistic infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Toxoplasma encephalitis in an infant with acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Invasive aspergillosis in human immunodeficiency virus-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Efficacy and safety of dapsone prophylaxis against Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV Infections in Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Frequent recurrence and persistence of varicella-zoster virus infections in children infected with human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Fungemia in children infected with the human immunodeficiency virus: new epidemiologic patterns, emerging pathogens, and improved outcome with antifungal therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

Nontuberculous mycobacteria in children with acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970196-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0031-3955(05)70196-6

1 reference

29 July 2017

1 reference